Clinical Trials

Chemotherapy

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

LEARN MORE

First Line Therapy

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants with Locally Advanced or Metastatic Cholangiocarcinoma with an IDH1 Mutation

LEARN MORE

Beyond First Line Therapy

A phase II study of pemigatinib plus durvalumab (MEDI4736) in previously treated advanced intrahepatic cholangiocarcinoma patients with FGFR-2 fusion or rearrangement

LEARN MORE

Beyond First Line Therapy

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants with Cancer Harboring BRAF Alterations

LEARN MORE

Immunotherapy

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

LEARN MORE

Beyond First Line Therapy

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

LEARN MORE

Chemotherapy

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (TOPAZ-1)

LEARN MORE

Beyond First Line Therapy

Phase IIb trial of pemigatinib in combination with atezolizumab and bevacizumab for treatment of advanced cholangiocarcinoma with FGFR2 fusion

LEARN MORE

Beyond First Line Therapy

Alliance EAY191-A6: A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations

LEARN MORE

Beyond First Line Therapy

GNS561-221-1

LEARN MORE

Beyond First Line Therapy

A Phase Ia/Ib Study of the Combination of the FGFR inhibitor Pemigatinib and the EGFR inhibitor Afatinib in Advanced Refractory Solid Tumors

LEARN MORE

Beyond First Line Therapy

A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumors (MAST).

LEARN MORE